Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565634 | 0.87 | CA2 (0.50) | CA1CA2CA9MAPK1CA12 | |
| Hydrochloric Acid SCHEMBL29970039 | 0.83 | CA2 (0.53) | CA1CA2CA9MAPK1PTGS2 | |
| SCHEMBL5850523 | 0.81 | PTGS1 (0.47) | PTGS1PTGS2LMNATDP1CTSL | |
| SCHEMBL5700053 | 0.81 | PTGS2 (0.59) | PTGS1PTGS2LMNATDP1CTSL | |
| SCHEMBL28216449 | 0.80 | CA2 (0.47) | CA1CA2CA9MAPK1PTGS1 | |
| SCHEMBL12474849 | 0.80 | CA1 (0.47) | CA1CA2CA9MAPK1PTGS1 | |
| SCHEMBL8514484 | 0.80 | CA2 (0.50) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL29233670 | 0.77 | PTGS1 (0.44) | CA1CA2CA9MAPK1PTGS1 | |
| SCHEMBL29718566 | 0.77 | CA2 (0.47) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL790692 | 0.76 | CA1 (0.52) | CA1CA2CA9MAPK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822002-A | A kind of method of ultrasonic wave added synthesis N- aryl sulfonic acid amides | 中南大学 | 2018-11-16 | — | — | CN | disclosed |
| CN-107922362-A | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2018-04-17 | — | — | CN | disclosed |
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| CN-1097051-C | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 2002-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | CA1 4155/4885CA2 3704/4885CA9 3940/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | CA1 4515/4885CA2 3559/4885CA9 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.